{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:09:57Z","timestamp":1793329797808,"version":"4.5.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031531","name":"Travere Therapeutics","doi-asserted-by":"crossref","award":["na"],"award-info":[{"award-number":["na"]}],"id":[{"id":"10.13039\/100031531","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2026,4]]},"abstract":"\n Key Points<\/jats:title>\n \n \n \n Sparsentan lowered proteinuria, with more frequent complete remission of proteinuria versus irbesartan in patients with genetic forms of FSGS.<\/jats:p>\n <\/jats:list-item>\n \n Fewer patients with genetic forms of FSGS progressed to the composite kidney endpoint with sparsentan versus irbesartan.<\/jats:p>\n <\/jats:list-item>\n \n Consistent with the overall DUPLEX population, the results support sparsentan's antiproteinuric benefit in patients with genetic forms of FSGS.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n \n FSGS is a podocytopathy that is diagnosed based on characteristic histopathologic lesions. Certain forms of FSGS with underlying genetic variants associated with the disease, including variants in podocyte proteins, as well as apolipoprotein L1 (\n APOL1<\/jats:italic>\n ) risk alleles, and variants in collagen type 4\n \u03b1<\/jats:italic>\n 3,\n \u03b1<\/jats:italic>\n 4, and\n \u03b1<\/jats:italic>\n 5 (\n COL4A3\u20135<\/jats:italic>\n ) proteins, are typically resistant to current treatments.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n The DUPLEX clinical trial assessed the efficacy and safety of sparsentan, a dual endothelin angiotensin receptor antagonist, in patients with biopsy-proven or genetic FSGS (gFSGS) and demonstrated a greater antiproteinuric effect over 108 weeks compared with the active control irbesartan. This\n post hoc<\/jats:italic>\n , exploratory analysis assessed the efficacy of sparsentan in the subset of patients enrolled in DUPLEX who had pathogenic variants in genes coding for podocyte proteins,\n COL4A3\u20135<\/jats:italic>\n variants, and\n APOL1<\/jats:italic>\n high-risk genotypes, all together referred to as gFSGS.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Next-generation sequencing identified 31 patients with podocyte gene variants, 25 with\n COL4A3\u20135<\/jats:italic>\n gene variants, and 14 with\n APOL1<\/jats:italic>\n high-risk genotypes. Baseline characteristics varied between genetic subgroups, with slightly younger patients, on average, in the podocyte gene variant group, and more African American patients in the\n APOL1<\/jats:italic>\n high-risk genotype group. In this exploratory analysis, sparsentan treatment resulted in substantial and sustained proteinuria reductions and numerically more frequent complete remission of proteinuria compared with irbesartan, consistent with observations in the full DUPLEX study population. Moreover, a lower proportion of sparsentan-treated versus irbesartan-treated patients reached composite kidney endpoints.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n These findings support sparsentan's antiproteinuric benefit in patients with gFSGS, a subgroup that is often resistant to other therapeutic interventions.<\/jats:p>\n <\/jats:sec>\n \n Clinical Trial registry name and registration number:<\/jats:title>\n Clinicaltrials.gov, NCT03493685.<\/jats:p>\n <\/jats:sec>","DOI":"10.2215\/cjn.0000000948","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T17:00:44Z","timestamp":1766509244000},"page":"605-614","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Antiproteinuric Effect of Sparsentan in Patients with Genetic-Associated FSGS Enrolled in the DUPLEX Trial"],"prefix":"10.2215","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1306-9037","authenticated-orcid":false,"given":"Jennifer","family":"Yee","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0336-7137","authenticated-orcid":false,"given":"Wu","family":"Gong","sequence":"additional","affiliation":[{"name":"Travere Therapeutics, Inc., San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jula","family":"Inrig","sequence":"additional","affiliation":[{"name":"Travere Therapeutics, Inc., San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2494-3970","authenticated-orcid":false,"given":"Michelle N.","family":"Rheault","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8054-8147","authenticated-orcid":false,"given":"Angela J.","family":"Gruber","sequence":"additional","affiliation":[{"name":"PreventionGenetics, Marshfield, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6121-3784","authenticated-orcid":false,"given":"Patricia W.","family":"Bedard","sequence":"additional","affiliation":[{"name":"Travere Therapeutics, Inc., San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7814-5324","authenticated-orcid":false,"given":"Radko","family":"Komers","sequence":"additional","affiliation":[{"name":"Travere Therapeutics, Inc., San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7778-292X","authenticated-orcid":false,"given":"Howard","family":"Trachtman","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"issue":"4S","key":"B1-20260417","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int."},{"issue":"9","key":"B2-20260417","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1159\/000508099","article-title":"Focal segmental glomerulosclerosis: state-of-the-art and clinical perspective","volume":"144","author":"Shabaka","year":"2020","journal-title":"Nephron."},{"issue":"4","key":"B3-20260417","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int."},{"issue":"4","key":"B4-20260417","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1053\/j.akdh.2024.04.001","article-title":"Genetic causes of nephrotic syndrome and focal and segmental glomerulosclerosis","volume":"31","author":"Caparali","year":"2024","journal-title":"Adv Kidney Dis Health."},{"issue":"5","key":"B5-20260417","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41581-022-00538-3","article-title":"The evolving story of apolipoprotein L1 nephropathy: the end of the beginning","volume":"18","author":"Daneshpajouhnejad","year":"2022","journal-title":"Nat Rev Nephrol."},{"issue":"8","key":"B6-20260417","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nrneph.2016.87","article-title":"The expanding phenotypic spectra of kidney diseases: insights from genetic studies","volume":"12","author":"Stokman","year":"2016","journal-title":"Nat Rev Nephrol."},{"issue":"9","key":"B7-20260417","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1681\/ASN.2013010113","article-title":"APOL1 variants associate with increased risk of CKD among African Americans","volume":"24","author":"Foster","year":"2013","journal-title":"J Am Soc Nephrol."},{"issue":"23","key":"B8-20260417","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1056\/NEJMoa1310345","article-title":"APOL1 risk variants, race, and progression of chronic kidney disease","volume":"369","author":"Parsa","year":"2013","journal-title":"N Engl J Med."},{"issue":"9","key":"B9-20260417","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/j.ekir.2022.06.001","article-title":"Heterozygous pathogenic COL4A3 and COL4A4 variants (autosomal dominant Alport syndrome) are common, and not typically associated with end-stage kidney failure, hearing loss, or ocular abnormalities","volume":"7","author":"Savige","year":"2022","journal-title":"Kidney Int Rep."},{"issue":"12","key":"B10-20260417","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1093\/ndt\/gfab334","article-title":"Heterozygous COL4A3\/COL4A4 mutations: the hidden part of the iceberg?","volume":"37","author":"Mastrangelo","year":"2022","journal-title":"Nephrol Dial Transplant."},{"issue":"6","key":"B11-20260417","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/ndt\/gfv325","article-title":"Collagen (COL4A) mutations are the most frequent mutations underlying adult focal segmental glomerulosclerosis","volume":"31","author":"Gast","year":"2016","journal-title":"Nephrol Dial Transplant."},{"issue":"4","key":"B12-20260417","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000435789","article-title":"Carriers of autosomal recessive Alport syndrome with thin basement membrane nephropathy presenting as focal segmental glomerulosclerosis in later life","volume":"130","author":"Deltas","year":"2015","journal-title":"Nephron."},{"issue":"11","key":"B13-20260417","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1681\/ASN.2007040444","article-title":"COL4A3\/COL4A4 mutations producing focal segmental glomerulosclerosis and renal failure in thin basement membrane nephropathy","volume":"18","author":"Voskarides","year":"2007","journal-title":"J Am Soc Nephrol."},{"issue":"11","key":"B14-20260417","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1042\/CS20240249","article-title":"Mechanism of protective actions of sparsentan in the kidney: lessons from studies in models of chronic kidney disease","volume":"138","author":"Kohan","year":"2024","journal-title":"Clin Sci (Lond)."},{"issue":"10","key":"B15-20260417","doi-asserted-by":"crossref","first-page":"R877","DOI":"10.1152\/ajpregu.00425.2015","article-title":"Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease","volume":"310","author":"Komers","year":"2016","journal-title":"Am J Physiol Regul Integr Comp Physiol."},{"issue":"5","key":"B16-20260417","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1053\/j.ackd.2014.05.009","article-title":"The pathogenesis of focal segmental glomerulosclerosis","volume":"21","author":"Jefferson","year":"2014","journal-title":"Adv Chronic Kidney Dis."},{"issue":"26","key":"B17-20260417","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa2308550","article-title":"Sparsentan versus irbesartan in focal segmental glomerulosclerosis","volume":"389","author":"Rheault","year":"2023","journal-title":"N Engl J Med."},{"issue":"4","key":"B18-20260417","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ekir.2019.12.017","article-title":"Study design of the phase 3 sparsentan versus irbesartan (DUPLEX) study in patients with focal segmental glomerulosclerosis","volume":"5","author":"Komers","year":"2020","journal-title":"Kidney Int Rep."},{"issue":"4","key":"B19-20260417","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.ekir.2024.01.032","article-title":"Focal segmental glomerulosclerosis patient baseline characteristics in the sparsentan phase 3 DUPLEX study","volume":"9","author":"Trachtman","year":"2024","journal-title":"Kidney Int Rep."},{"issue":"3","key":"B20-20260417","doi-asserted-by":"crossref","first-page":"414","DOI":"10.2215\/CJN.04780517","article-title":"An outcomes-based definition of proteinuria remission in focal segmental glomerulosclerosis","volume":"13","author":"Troost","year":"2018","journal-title":"Clin J Am Soc Nephrol."},{"issue":"5","key":"B21-20260417","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med."},{"issue":"3","key":"B22-20260417","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/ng.2898","article-title":"Mutation-dependent recessive inheritance of NPHS2-associated steroid-resistant nephrotic syndrome","volume":"46","author":"Tory","year":"2014","journal-title":"Nat Genet."},{"issue":"3","key":"B23-20260417","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1053\/j.ajkd.2018.06.034","article-title":"Nephrotic syndrome with mutations in NPHS2: the role of R229Q and implications for genetic counseling","volume":"73","author":"Rood","year":"2019","journal-title":"Am J Kidney Dis."},{"issue":"2","key":"B24-20260417","doi-asserted-by":"crossref","first-page":"100","DOI":"10.7326\/M17-1319","article-title":"Whole-exome sequencing in adults with chronic kidney disease: a pilot study","volume":"168","author":"Lata","year":"2018","journal-title":"Ann Intern Med."},{"issue":"2","key":"B25-20260417","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1806891","article-title":"Diagnostic utility of exome sequencing for kidney disease","volume":"380","author":"Groopman","year":"2019","journal-title":"N Engl J Med."},{"issue":"5993","key":"B26-20260417","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1193032","article-title":"Association of trypanolytic ApoL1 variants with kidney disease in African Americans","volume":"329","author":"Genovese","year":"2010","journal-title":"Science."},{"issue":"4","key":"B27-20260417","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.kint.2016.10.013","article-title":"Genomic and clinical profiling of a national nephrotic syndrome cohort advocates a precision medicine approach to disease management","volume":"91","author":"Bierzynska","year":"2017","journal-title":"Kidney Int."},{"issue":"1","key":"B28-20260417","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5414\/CN107320","article-title":"Mutations in podocyte genes are a rare cause of primary FSGS associated with ESRD in adult patients","volume":"78","author":"B\u00fcscher","year":"2012","journal-title":"Clin Nephrol."},{"issue":"1","key":"B29-20260417","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1681\/ASN.2013111155","article-title":"Heterogeneous genetic alterations in sporadic nephrotic syndrome associate with resistance to immunosuppression","volume":"26","author":"Giglio","year":"2015","journal-title":"J Am Soc Nephrol."},{"issue":"6","key":"B30-20260417","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1681\/ASN.2014050489","article-title":"A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome","volume":"26","author":"Sadowski","year":"2015","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"B31-20260417","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2215\/CJN.04120417","article-title":"Whole exome sequencing of patients with steroid-resistant nephrotic syndrome","volume":"13","author":"Warejko","year":"2018","journal-title":"Clin J Am Soc Nephrol."},{"issue":"7","key":"B32-20260417","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1681\/ASN.2015050504","article-title":"Using population genetics to interrogate the monogenic nephrotic syndrome diagnosis in a case cohort","volume":"27","author":"Sampson","year":"2016","journal-title":"J Am Soc Nephrol."},{"issue":"2","key":"B33-20260417","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1053\/snep.2003.50014","article-title":"The genetic basis of FSGS and steroid-resistant nephrosis","volume":"23","author":"Pollak","year":"2003","journal-title":"Semin Nephrol."},{"issue":"3","key":"B34-20260417","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/01.ASN.0000118135.00519.B0","article-title":"Podocin and nephrotic syndrome: implications for the clinician","volume":"15","author":"Niaudet","year":"2004","journal-title":"J Am Soc Nephrol."},{"issue":"6","key":"B35-20260417","doi-asserted-by":"crossref","first-page":"100826","DOI":"10.1016\/j.xkme.2024.100826","article-title":"A review of focal segmental glomerulosclerosis classification with a focus on genetic associations","volume":"6","author":"Bonilla","year":"2024","journal-title":"Kidney Med."},{"issue":"6","key":"B36-20260417","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/jmcb\/mju040","article-title":"COL4A3 mutations cause focal segmental glomerulosclerosis","volume":"6","author":"Xie","year":"2014","journal-title":"J Mol Cell Biol."},{"issue":"1","key":"B37-20260417","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000529227","article-title":"APOL1 and APOL1-Associated kidney disease: a common disease, an unusual disease gene - proceedings of the Henry Shavelle professorship","volume":"3","author":"Pollak","year":"2023","journal-title":"Glomerular Dis."},{"issue":"10","key":"B38-20260417","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41573-021-00242-0","article-title":"The glomerular filtration barrier: a structural target for novel kidney therapies","volume":"20","author":"Daehn","year":"2021","journal-title":"Nat Rev Drug Discov."},{"issue":"3","key":"B39-20260417","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/MNH.0000000000000704","article-title":"Apolipoprotein L1 and mechanisms of kidney disease susceptibility","volume":"30","author":"Bruggeman","year":"2021","journal-title":"Curr Opin Nephrol Hypertens."},{"issue":"3","key":"B40-20260417","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2404211","article-title":"APOL1 Bi- and monoallelic variants and chronic kidney disease in West Africans","volume":"392","author":"Gbadegesin","year":"2025","journal-title":"N Engl J Med."},{"issue":"4","key":"B41-20260417","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1681\/ASN.2004070593","article-title":"Focal and segmental glomerulosclerosis: definition and relevance of a partial remission","volume":"16","author":"Troyanov","year":"2005","journal-title":"J Am Soc Nephrol."},{"issue":"2","key":"B43-20260417","first-page":"14","article-title":"Community collaborates to address clinical trial endpoints for FSGS","volume":"16","author":"West","year":"2024","journal-title":"Kidney News."},{"issue":"19","key":"B44-20260417","doi-asserted-by":"crossref","first-page":"e177775","DOI":"10.1172\/jci.insight.177775","article-title":"Sparsentan improves glomerular hemodynamics, cell functions, and tissue repair in a mouse model of FSGS","volume":"9","author":"Gyarmati","year":"2024","journal-title":"JCI Insight."},{"issue":"3","key":"B45-20260417","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/path.6087","article-title":"Dual inhibition of the endothelin and angiotensin receptor ameliorates renal and inner ear pathologies in Alport mice","volume":"260","author":"Cosgrove","year":"2023","journal-title":"J Pathol."},{"issue":"5","key":"B46-20260417","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/ki.2014.143","article-title":"Endothelin and endothelin antagonists in chronic kidney disease","volume":"86","author":"Kohan","year":"2014","journal-title":"Kidney Int."}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000000948","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:36:39Z","timestamp":1786368999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000000948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.0000000948","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"2025-06-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}